Deprescribing challenges in elderly patients at high cardiovascular risk

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background: Optimizing therapy in patients at extremely high cardiovascular risk requires a balance between treatment effectiveness and the risk of polypharmacy. The concept of deprescribing is considered a promising approach to reducing the potential harm of drug therapy, including in patient groups at extremely high cardiovascular risk.

Objective: Critical evaluation of the effectiveness of a personalized approach to reducing polypharmacy by adapting treatment regimens with lipid-lowering agents, proton pump inhibitors, antihypertensive agents, and dual antiplatelet therapy based on a review of the scientific literature with elements of a systematic analysis.

Materials and methods: A search of the PubMed and Google Scholar databases was conducted from February to April 2025. Publications published between March 2019 and March 2025 were included in the analysis; the following set of keywords was used to generate the sample: deprescribing; arterial hypertension; antihypertensives; older adults; proton pump inhibitors; rosuvastatin; atorvastatin; cardiovascular disease; DAPT; prospective study; retrospective study; placebo-controlled.

Results: A pooled analysis of data from randomized and observational studies demonstrates the safety and efficacy of controlled decrease or discontinuation of these medications with strict risk stratification and dynamic monitoring. Targeted deprescribing can lead to a reduction in the incidence of side effects, a decrease in the number of drug interactions, and an improvement in adherence to therapy; however, in some patients, drug discontinuation is associated with the risk of adverse clinical outcomes.

Conclusion: Deprescribing in patients with extremely high cardiovascular risk is a clinically valid strategy for optimizing pharmacotherapy. Safe implementation of this approach requires consideration of the potential risks of drug discontinuation, comorbidities, and the patient’s functional status, as well as dynamic monitoring.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Nadezhda Izmozherova

Ural State Medical University

Хат алмасуға жауапты Автор.
Email: nadezhda_izm@mail.ru
ORCID iD: 0000-0001-7826-9657

Dr. Sci. (Med.), Associate Professor, Head of the Department of Pharmacology and Clinical Pharmacology, Chief External Expert in Clinical Pharmacology of the Ministry of Health of the Sverdlovsk Region

Ресей, Yekaterinburg

M. Shambatov

Ural State Medical University

Email: nadezhda_izm@mail.ru
ORCID iD: 0000-0001-7312-415X
Ресей, Yekaterinburg

D. Erlish

Ural State Medical University

Email: nadezhda_izm@mail.ru
ORCID iD: 0009-0000-9492-683X
Ресей, Yekaterinburg

Ya. Kolnogorova

Ural State Medical University

Email: nadezhda_izm@mail.ru
ORCID iD: 0009-0008-6042-9366
Ресей, Yekaterinburg

Әдебиет тізімі

  1. Visseren F.L.J., Mach F., Smulders Y.M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484
  2. Canadian Deprescribing Network. Evidence-based deprescribing guidelines [Internet]. Deprescribing.org; 2022 [cited 2025 Mar 18]. Available from: https://www.deprescribing.org
  3. American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(5):2052-2081. https://doi.org/10.1111/jgs.18372
  4. Odden M.C., Graham L.A., Liu X., et al. Antihypertensive deprescribing and cardiovascular events among long-term care residents. JAMA Netw Open. 2024;7(11):e2446851. https://doi.org/10.1001/jamanetworkopen.2024.46851
  5. Xie M., You J.H.S. Deprescribing proton pump inhibitors in older adults: a cost-effectiveness analysis. PLoS ONE. 2024;19(10):e0311658. https://doi.org/10.1371/journal.pone.0311658
  6. Peersen K., Munkhaugen J., Sverre E., et al. Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC Cardiovasc Disord. 2021;21(1):596. https://doi.org/10.1186/s12872-021-02422-7
  7. Min P.K., Kang T.S., Cho Y.H., et al.; SHARE Investigators. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial. JAMA Netw Open. 2024;7(3):e240877. https://doi.org/10.1001/jamanetworkopen.2024.0877
  8. Liu X., Steinman M.A., Lee S.J., et al. Systolic blood pressure, antihypertensive treatment, and cardiovascular and mortality risk in VA nursing home residents. J Am Geriatr Soc. 2023;71(7):2131-2140. https://doi.org/10.1111/jgs.18301
  9. Vu M., Sileanu F.E., Aspinall S.L., et al. Antihypertensive deprescribing in older adult veterans at end of life admitted to Veteran Affairs nursing homes. J Am Med Dir Assoc. 2021;22(1):132-140.e5. https://doi.org/10.1016/j.jamda.2020.05.060
  10. Sheppard J.P., Burt J., Lown M., et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA. 2020;323(20):2039-2051. https://doi.org/10.1001/jama.2020.4871
  11. Springer S.P., Mor M.K., Sileanu F., et al. Incidence and predictors of aspirin discontinuation in older adult veteran nursing home residents at end of life. J Am Geriatr Soc. 2020;68(4):725-735. https://doi.org/10.1111/jgs.16346.
  12. Bogaerts J.M.K., Gussekloo J., de Jong-Schmit B.E.M., et al. Effects of the discontinuation of antihypertensive treatment on neuropsychiatric symptoms and quality of life in nursing home residents with dementia (DANTON): a multicentre, open-label, blinded-outcome, randomised controlled trial. Age Ageing. 2024;53(7):afae133. https://doi.org/10.1093/ageing/afae133
  13. Honda K., Goto K., Maeda M., et al. Association Between Antihypertensive Treatment Discontinuation and the Development of Intracerebral Hemorrhage in Japanese Patients With Hypertension: The LIFE Study. J Am Heart Assoc. 2025;14(16):e042523. https://doi.org/10.1161/JAHA.125.042523
  14. Li Z.H., Zhong W.F., Qiu C.S., et al. Association between regular proton pump inhibitors use and cardiovascular outcomes: A large prospective cohort study. Int J Cardiol. 2024;395:131567. https://doi.org/10.1016/j.ijcard.2023.131567
  15. Rooney M.R., Bell E..J., Alonso A., et al. Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study. J Clin Gastroenterol. 2021;55(8):677-683. https://doi.org/10.1097/MCG.0000000000001420
  16. Fan W., Liu H., Shen Y., Hong K. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients. Cardiovasc Drugs Ther. 2024;38(3):517-525. https://doi.org/10.1007/s10557-023-07425-4
  17. Abrahami D., McDonald E.G., Schnitzer M.E., et al. Proton pump inhibitors and risk of gastric cancer: population-based cohort sudy. Gut. 2022;71:16-24. https://doi.org/10.1136/gutjnl-2021-325097
  18. Barraquer Comes A., Roy Millán P. Proton Pump Inhibitor Deprescription Prospective Study in Patients Without Indication: Are There Differences in Proportion of Restarts According to Withdrawal Strategy? J Pharm Technol. 2023;39(5):224-230. https://doi.org/10.1177/87551225231195216
  19. Shi W., Ni L., Yang J., et al. The Clinical Impact of Proton Pump Inhibitors When Co-Administered With Dual Antiplatelet Therapy in Patients Having Acute Myocardial Infarction With Low Risk of Gastrointestinal Bleeding: Insights From the China Acute Myocardial Infarction Registry. Front Cardiovasc Med. 2021;8:685072. https://doi.org/10.3389/fcvm.2021.685072
  20. Sasaki S., Ota K., Sanomura M., et al. Widespread use of proton pump inhibitors or potassium-competitive acid blocker has changed the status of gastrointestinal bleeding in patients with ischemic heart disease: real-world data from high volume centers. BMC Gastroenterol. 2024;24(1):177. https://doi.org/10.1186/s12876-024-03269-w
  21. Zhou Y.F., Wang Y., Wang G., et al. Association Between Statin Use and Progression of Arterial Stiffness Among Adults With High Atherosclerotic Risk. JAMA Netw Open. 2022;5(6):e2218323. https://doi.org/10.1001/jamanetworkopen.2022.18323
  22. Giral P., Neumann A., Weill A., Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40(43):3516-3525. https://doi.org/10.1093/eurheartj/ehz458
  23. Fayol A., Schiele F., Ferrières J., et al.; FAST-MI Investigators. Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults. Circ Cardiovasc Qual Outcomes. 2024;17(5):e010685. https://doi.org/10.1161/CIRCOUTCOMES.123.010685
  24. Fstkchian A.K., Lowe R.N., Saseen J.J. Statin Therapy Prescribing in Atherosclerotic Cardiovascular Disease Patients with Chronic Kidney Disease. J Am Pharm Assoc (2003). 2025 Mar 28:102395. https://doi.org/10.1016/j.japh.2025.102395
  25. Kristiansen O., Vethe N.T., Peersen K., et al. Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. Eur Heart J Cardiovasc Pharmacother. 2021;7(6):507-516. https://doi.org/10.1093/ehjcvp/pvaa076
  26. Noaman S., Al-Mukhtar O., Abramovic S., et al. Changes in Statin Prescription Patterns in Patients Admitted to an Australian Geriatric Subacute Unit. Heart Lung Circ. 2019;28(3):423-429. https://doi.org/10.1016/j.hlc.2017.12.009
  27. Fan C.H., Hao Y., Liu Y.H., et al. Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups. BMC Cardiovasc Disord. 2020;20(1):330. https://doi.org/10.1186/s12872-020-01604-z.
  28. Suliman I., Batarfi A., Almohammadi H., et al. Prevalence of Self-Reported Muscle Pain Among Statin Users From National Guard Hospital, Riyadh. Cureus. 2022;14(3):e23463. https://doi.org/10.7759/cureus.23463
  29. Thompson W., Jarbøl D.E., Nielsen J.B., et al. Statin use and discontinuation in Danes age 70 and older: a nationwide drug utilisation study. Age Ageing. 2021;50(2):554-558. https://doi.org/10.1093/ageing/afaa160
  30. Desjobert E., Tea V., Schiele F., et al.; FAST-MI investigators. Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: The FAST-MI registries. Arch Cardiovasc Dis. 2021;114(2):88-95. https://doi.org/10.1016/j.acvd.2020.06.003
  31. Yao X., Shah N.D., Gersh B.J., et al. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. JAMA Netw Open. 2020;3(11):e2025505. https://doi.org/10.1001/jamanetworkopen.2020.25505
  32. Stürzebecher P.E., Katzmann J.L., Gouni-Berthold I., et al.; Statin Intolerance Registry investigators. Treatment strategies and LDL cholesterol target attainment in patients with statinintolerance: Insights from the multicentre statin intolerance registry. Am J Prev Cardiol. 2025;21:100953. https://doi.org/10.1016/j.ajpc.2025.100953
  33. Zhou Z., Curtis A.J., Ernst M.E., et al. Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. Eur J Clin Pharmacol. 2022;78(3):467-476. https://doi.org/10.1007/s00228-021-03239-1
  34. Thalmann I., Preiss D., Schlackow I., et al. Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017. Heart. 2023;109(5):388-395. https://doi.org/10.1136/heartjnl-2022-321452
  35. Visseren F.L.J., Mach F., Smulders Y.M., et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484
  36. Hahn J.Y., Song Y.B., Oh J.H., et al.; SMART-CHOICE Investigators. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321(24):2428-2437. https://doi.org/10.1001/jama.2019.8146
  37. Choi K.H., Park Y.H., Song Y.B., et al.; SMART-CHOICE Investigators. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial. JAMA Cardiol. 2022;7(11):1100-1108. https://doi.org/10.1001/jamacardio.2022.3203
  38. Yamamoto K., Natsuaki M., Watanabe H., et al. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention. J Am Coll Cardiol Intv. 2024 May, 17(9)1119–1130. https://doi.org/10.1016/j.jcin.2024.03.017
  39. Valgimigli M., Smits P.C., Frigoli E., et al.; MASTER DAPT Investigators. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J. 2022;43(33):3100-3114. https://doi.org/10.1093/eurheartj/ehac284
  40. Mehran R., Baber U., Sharma S.K., et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381(21):2032-2042. https://doi.org/10.1056/NEJMoa1908419
  41. Kim B.K., Hong S.J., Cho Y.H., et al.; TICO Investigators. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA. 2020;323(23):2407-2416. https://doi.org/10.1001/jama.2020.7580
  42. Ge Z., Kan J., Gao X., et al.; ULTIMATE-DAPT investigators. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024;403(10439):1866-1878. https://doi.org/10.1016/S0140-6736(24)00473-2
  43. Lee M., Byun S., Lim S., et al.; TALOS-AMI Investigators. Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial. JAMA Cardiol. 2024;9(2):125-133. https://doi.org/10.1001/jamacardio.2023.4587
  44. Shin E.S., Her A.Y., Kim B., et al.; SMART-CHOICE Investigators. Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. J Korean Med Sci. 2023;38(45):e383. https://doi.org/10.3346/jkms.2023.38.e383
  45. D’Ascenzo F., Bertaina M., Fioravanti F., et al. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. Eur J Prev Cardiol. 2020;27(7):696-705. https://doi.org/10.1177/2047487319836327
  46. Sorrentino S., Sartori S., Baber U., et al. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ Cardiovasc Interv. 2020;13(4):e008226. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008226
  47. Седых Д.Ю., Кашталап В.В., Велиева Р.М., Барбараш О.Л. Возможности шкалы PRECISE-DAPT в прогнозировании риска ишемических и геморрагических событий при инфаркте миокарда с подъемом сегмента ST (по данным регистрового исследования г. Кемерово). РФК. 2019;(6). [Sedykh D.Yu., Kashtalap V.V., Velieva R.M., Barbarash O.L. Possibilities of the PRECISE-DAPT scale in predicting the risk of ischemic and hemorrhagic events in ST-segment elevation myocardial infarction (according to the registry study of Kemerovo). Russian Journal of Cardiology. 2019;(6). (In Russ.)]. https://doi.org/10.20996/1819-6446-2019-15-6-806-812
  48. Рунихина Н.К., Черняева М.С., Малая И.П. и др. STOPP/START критерии: версия 3. Обновленный инструмент для борьбы с полипрагмазией у гериатрических пациентов. Российский журнал гериатрической медицины. 2023;16(4):273-288. [Kotovskaya Yu.V., Tkacheva O.N., Runikhina N.K., et al. Enhanced STOPP/START Criteria: A Tool for Managing Polypharmacy in Older Population. Russian Journal of Geriatric Medicine. 2023;16(4):273-288. (In Russ.)]. https://doi.org/10.37586/2686-8636-4-2023-273-288

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Figure. Publication selection strategy 

Жүктеу (223KB)
Метадеректер

© Bionika Media, 2025